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tor (bFGF) are two potent stimulators of angiogenesis
that are elevated in the serum of patients with many
types of cancer.2,3 The production of both factors is
known to be upregulated in response to hypoxia.4,5 We
hypothesized that one or both of these angiogenic fac-
tors may mediate the abnormal angiogenesis demon-
strated by children with cyanotic congenital heart dis-
ease. We compared VEGF and bFGF in the serum of
children with and without cyanotic congenital heart dis-
ease to determine whether systemic levels of these
angiogenic factors were elevated in the presence of
cyanosis.
Methods
Blood was collected during elective cardiac catheterization
from 22 children with cyanotic congenital heart disease and
19 children with acyanotic congenital heart disease. Patients
were excluded if they had undergone operative procedures
that converted previously cyanotic conditions to an acyanotic
A bnormal angiogenesis occurs in association withnumerous conditions, including tumor metastasis,
diabetic retinopathy, rheumatoid arthritis, and gastric
ulceration.1 Children with cyanotic congenital heart dis-
ease often experience the development of abnormal
blood vessel proliferation, which may also represent a
form of abnormal angiogenesis. Vascular endothelial
growth factor (VEGF) and basic fibroblast growth fac-
Objective: Vascular endothelial growth factor and basic fibroblast growth
factor are potent stimulators of angiogenesis. Children with cyanotic
congenital heart disease often experience the development of wide-
spread formation of collateral blood vessels, which may represent a
form of abnormal angiogenesis. We undertook the present study to
determine whether children with cyanotic congenital heart disease have
elevated serum levels of vascular endothelial growth factor and basic
fibroblast growth factor. Methods: Serum was obtained from 22 children
with cyanotic congenital heart disease and 19 children with acyanotic
heart disease during cardiac catheterization. Samples were taken from
the superior vena cava, inferior vena cava, and a systemic artery.
Vascular endothelial growth factor and basic fibroblast growth factor
levels were measured in the serum from each of these sites by
enzyme–linked immunosorbent assay. Results: Vascular endothelial
growth factor was significantly elevated in the superior vena cava (P =
.04) and systemic artery (P = .02) but not in the inferior vena cava (P =
.2) of children with cyanotic congenital heart disease compared to chil-
dren with acyanotic heart disease. The mean vascular endothelial
growth factor level, determined by averaging the means of all 3 sites,
was also significantly elevated (P = .03). Basic fibroblast growth factor
was only significantly elevated in the systemic artery (P = .02).
Conclusion: Children with cyanotic congenital heart disease have elevat-
ed systemic levels of vascular endothelial growth factor. These findings
suggest that the widespread formation of collateral vessels in these chil-
dren may be mediated by vascular endothelial growth factor. (J Thorac
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state (Fontan procedure). Patients were also excluded if they
had a history of malignancy or inflammatory states that might
lead to increased levels of VEGF or bFGF independent of
their oxygen saturation. The study was approved by the
Institutional Review Board of the Children’s Hospital and
Regional Medical Center, Seattle, Washington, and all proce-
dures were performed in accordance with their guidelines
after obtaining informed consent. 
Blood was collected from the superior vena cava (SVC),
inferior vena cava (IVC), and a systemic artery by way of
indwelling catheters at the time of cardiac catheterization.
Samples were allowed to clot for 30 minutes and were then
centrifuged at 3000g for 30 minutes at 4°C. Serum was
removed and stored at –70°C. VEGF and bFGF levels were
measured with the Quantikine VEGF and HS bFGF ELISA
kits (R&D Systems, Minneapolis, Minn) according to the
manufacturer’s instructions. In brief, serum samples were
added to wells precoated with VEGF or bFGF antibody and
incubated at room temperature for 2 or 3 hours, respectively.
VEGF antibody conjugated to horseradish peroxidase was
added followed by substrate (hydrogen peroxide) and chro-
mogen (tetramethylbenzidine). For the bFGF assay, bFGF
antibody conjugated to alkaline phosphatase was added fol-
lowed by substrate (NADPH) and chromogen (INT-Violet).
After stop solution (2N sulfuric acid) was added, optical den-
sity was determined within 30 minutes. Wells were read at a
wavelength of 450 nm with a correction at 545 nm (VEGF)
or 450 nm with a correction at 630 nm (bFGF). Each sample
was run 4 times, and the results were averaged, yielding a sin-
gle value for VEGF and bFGF for each site sampled. The
limit of detection was 9 pg/mL for VEGF and 0.50 pg/mL for
bFGF. Values of VEGF and bFGF less than the detection lim-
its of the assay were assigned values of 4.5 pg/mL and 0.25
pg/mL, respectively. 
Statistical analysis was carried out with SAS statistical
software, version 6.12 (SAS Institute Inc, Cary, NC). VEGF
and bFGF levels were determined for each site and are
expressed as median (25th, 75th percentile). VEGF and bFGF
levels for each patient were also averaged across sampling
sites. Wilcoxon rank sum was used to assess differences in
VEGF and bFGF levels between patients with cyanotic heart
disease and with acyanotic heart disease. Repeated measures
analysis of variance was used to determine whether the sam-
pling site was associated with VEGF or bFGF levels.
Results
The median age was 1.6 years (25%, 0.7; 75%, 3.7)
for children with cyanotic congenital heart disease and
12.2 years (25%, 6.9; 75%, 16.1) for children with
acyanotic congenital heart disease. Mean systemic
room air oxygen saturation was 79.8% ± 7.7% for chil-
dren with cyanotic congenital heart disease and 99.5%
± 1.0% for children with acyanotic congenital heart dis-
ease. There were 11 girls and 11 boys in the cyanotic
group and 9 girls and 10 boys in the acyanotic group.
Table I. Diagnosis and most recent procedure for patients with cyanotic congenital heart disease
Diagnosis Most recent procedure Patients (n)
Tetralogy of Fallot None 4
Tetralogy of Fallot Blalock-Taussig shunt 1
Hypoplastic left heart syndrome Norwood procedure 3
Hypoplastic left heart syndrome Bidirectional Glenn shunt 2
Pulmonary atresia, intact ventricular septum Blalock-Taussig shunt 2
Pulmonary atresia, intact ventricular septum Bidirectional Glenn shunt 1
Pulmonary atresia, transposition of the great arteries, Bidirectional Glenn shunt 1
ventricular septal defect
Heterotaxy, pulmonary stenosis Ventricular septal defect repair, 1
right ventricular outflow patch
Heterotaxy, pulmonary atresia Blalock-Taussig shunt 1
Heterotaxy, pulmonary atresia Bidirectional Glenn shunt 1
Unbalanced arteriovenous canal Pulmonary artery band 1
Tricuspid atresia Blalock-Taussig shunt 2
Tricuspid atresia Bidirectional Glenn shunt 1
Tricuspid atresia Waterston shunt 1
Total patients 22
Table II. Diagnosis for patients with acyanotic 
congenital heart disease
Diagnosis Patients (n)
Recurrent tachycardia 5
Aortic stenosis 4
Patent ductus arteriosus 3
Pulmonary stenosis 2
Aortic coarctation 1
Aortic coarctation, aortic stenosis 1
Aortic coarctation, mitral stenosis 1
Aortic coarctation, aortic stenosis, ventricular septal defect 1
Mitral stenosis, aortic insufficiency 1
Total patients 19
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The clinical diagnosis and past surgical procedures for
children with cyanotic congenital heart disease and the
clinical diagnosis for children with acyanotic congenital
heart disease are listed in Tables I and II, respectively.
Twenty-one of the patients with cyanotic congenital
heart disease and all of the patients with acyanotic con-
genital heart disease had serum VEGF measured. One
patient with cyanotic congenital heart disease did not
have VEGF measured because of lack of sufficient
sample. Not all children had samples available from all
three sites. Among patients with cyanotic congenital
heart disease (n = 21 patients), the VEGF level aver-
aged across all three sampling sites (SVC, IVC, and
systemic artery) was 129.6 pg/mL greater than in
patients with acyanotic congenital heart disease (n = 19
patients; P = .03; Fig 1). Among patients with cyanotic
congenital heart disease (n = 22 patients), the bFGF
level averaged across all three sampling sites was 3.5
pg/mL greater than in patients with acyanotic congeni-
tal heart disease (n = 19 patients) but this did not reach
statistical significance (P = .2; Fig 1).
The sites from which blood samples were obtained
did not significantly affect VEGF levels. Patients with
cyanotic congenital heart disease (n = 12 patients) had
a median arterial VEGF level 235.5 pg/mL greater than
patients with acyanotic congenital heart disease (n = 14
patients; P = .02; Fig 2). Samples obtained from the
SVC showed a similar pattern, with levels among
patients with cyanotic congenital heart disease (n = 11
patients) 136.0 pg/mL greater than patients with acyan-
otic congenital heart disease (n = 13 patients; P = .04).
For samples obtained from the IVC, VEGF levels tend-
ed to be higher among the patients with cyanotic con-
genital heart disease (n = 17 patients) than among the
patients with acyanotic congenital heart disease (n = 16
patients), but this was not statistically significant (P =
.2). 
Median arterial bFGF levels in cyanotic children (n =
14) were 10.7 pg/mL greater than in patients with
acyanotic congenital heart disease (n = 15 patients; P =
.02; Fig 3). Samples obtained from the SVC had bFGF
levels in patients with cyanotic congenital heart disease
(n = 13 patients) that were 7.5 pg/mL greater than
among patients with acyanotic congenital heart disease
(n = 14 patients; P = .09). For samples obtained from
Fig 1. Average VEGF and bFGF levels for the three sites
sampled (SVC, IVC, and systemic artery). Results are
expressed as median values; the error bars represent the 25th
and 75th percentiles. 
Fig 2. Median (25th, 75th percentile) VEGF levels in sys-
temic artery, SVC, and IVC in patients with cyanotic con-
genital heart disease and acyanotic children.
Fig 3. Median (25th, 75th percentile) bFGF levels in systemic
artery, SVC, and IVC in patients with cyanotic congenital
heart disease and acyanotic children.
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the IVC, bFGF levels were 3.0 pg/mL greater among
the patients with cyanotic congenital heart disease (n =
18 patients) than among the patients with acyanotic
congenital heart disease (n = 16 patients; P = .7). 
Discussion
Children with cyanotic congenital heart disease may
experience the development of abnormal vascular
channels that become the source of significant morbid-
ity. Abnormal blood vessel proliferation in these chil-
dren may take several forms, including systemic
venous collaterals, pulmonary arteriovenous malforma-
tions, or aortopulmonary collateral arteries.6-8 Systemic
venous collateral vessels may develop extensively in
any child with cyanotic congenital heart disease. Pul-
monary arteriovenous malformations developing after
cavopulmonary anastomosis in children with single
ventricle physiology cause progressive cyanosis from
right to left shunting. Aortopulmonary collateral arter-
ies associated with pulmonary atresia may cause a
number of problems, including significant left to right
shunting, progressive obliteration after unifocalization
procedures, and pulmonary “steal” from systemic
blood flow during cardiopulmonary bypass. The man-
agement of children with cyanotic congenital heart dis-
ease may be complicated by the development of these
vascular lesions and may require interventional cardiac
catheterization or surgical treatment.
The proliferative nature of these vascular channels
and their widespread occurrence suggest that these
lesions form in response to a systemic angiogenic stim-
ulus. Our interest in this area comes from previous
work that examined pulmonary arteriovenous malfor-
mations that develop in children after cavopulmonary
anastomosis. The development of these pulmonary
arteriovenous malformations may represent a more
localized form of abnormal angiogenesis that is under
hepatic control. Conditioned media derived from cul-
tured hepatocytes demonstrates an inhibitory effect on
endothelial proliferation, and this inhibitory activity
can be partially purified by serial column chromatogra-
phy.9 Presumably, the absence of this factor in the pul-
monary circulation after cavopulmonary anastomosis
might lead to unchecked vascular proliferation, result-
ing in clinically apparent pulmonary arteriovenous
malformations. 
The present study was undertaken to determine
whether systemic levels of stimulators of angiogenesis
were elevated in the serum of children with cyanotic
congenital heart disease. The role of VEGF and bFGF
as angiogenic stimulators is well established, and there-
fore these growth factors represent likely candidates for
mediating the abnormal proliferation of blood vessels
that occur in these children. Both of these factors have
been shown to be mitogenic for endothelial cells10,11
and act synergistically to induce angiogenesis.12
Elevated systemic levels of these factors have been
found in the sera of patients with cancer of many cell
types including lung, ovarian, uterine, colorectal, and
renal.2,3 Significant elevations of these factors in
patients with cancer correlate with a more aggressive
course, presumably because of an increased angiogenic
state of the tumor that leads to early metastasis.
Hypoxia is a strong stimulus for angiogenesis and
leads to an upregulation of both VEGF and bFGF dur-
ing hypoxic conditions in cell culture.4,5 Glioma cells
exposed to hypoxia demonstrate upregulation of VEGF
mRNA that is reversed when cells are returned to nor-
mal oxygen levels.4 Upregulation of VEGF has also
been demonstrated in vivo where VEGF messenger
RNA is increased 2- to 3–fold in the lungs of animals
exposed to chronic hypoxia.13 Recent reports have doc-
umented increased serum levels of VEGF in systemic
hypoxic conditions in humans. Asano and colleagues14
reported increased serum VEGF levels in athletes who
were trained at high altitude and then returned to normal
levels 1 month after the athletes returned to sea level.
There is also evidence that bFGF is upregulated by
hypoxia. The production of bFGF mRNA has been
found to increase in the brains of animals exposed to
hypoxia.5,15
The present study demonstrates that VEGF is elevat-
ed in the serum of children with cyanotic congenital
heart disease. This finding was consistent for serum
obtained from the SVC and the systemic artery and for
the average value obtained from all three sites. bFGF
was significantly elevated in the systemic artery of chil-
dren with cyanotic congenital heart disease, and there
was a trend toward increased bFGF levels in serum
obtained from the SVC and the average value from the
three sites. The lack of significant elevations of bFGF
may relate to the small sample size of this study.
However, based on the known biologic features of
these two angiogenic factors, it seems reasonable that
VEGF is more likely to be systemically elevated in
patients with cyanotic congenital heart disease. bFGF
lacks a signal sequence necessary for secretion, and it
is not known how bFGF is exported from cells.16 bFGF
has been shown to be stored in the extracellular matrix
and may be released from these extracellular storage
sites with cell injury or death.17 bFGF may not be
released into the circulation in these children with
chronic hypoxic without the cellular injury that occurs
in tumor proliferation or inflammatory states in which
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this factor is elevated. VEGF, on the other hand, does
contain a signal sequence and has been shown to be
secreted from cells.18
We sampled several vascular beds (SVC, IVC, and
systemic artery) in an attempt to identify the source of
production of these factors in these children. This strat-
egy might be predicted to be unsuccessful because of
the rapid equilibration and dilution of factors produced
by a given organ (the liver for example) in high-vol-
ume, high-flow vessels such as the great veins and the
arterial circulation. We were unable to definitively pin-
point the site of origin or metabolic breakdown of
either factor in these children. We are currently looking
at tissue protein and mRNA levels of VEGF and bFGF
in children with cyanotic congenital heart disease using
immunocytochemistry and in situ hybridization.
A weakness of this study is that the levels of VEGF
that were observed in children with cyanotic congenital
heart disease in this study were not appreciably differ-
ent from normal values that have been previously
obtained in some reports.19,20 Recent studies have
demonstrated that serum values of VEGF increase with
the time that blood is allowed to clot before being cen-
trifuged, possibly related to VEGF release by activated
platelets.21 Samples obtained for the present study were
kept on ice and centrifuged within 30 minutes of col-
lection. It is possible that the VEGF values obtained in
this study were generally lower than those previously
reported because we had minimal platelet activation in
our samples because of prompt processing. In addition,
other studies have demonstrated VEGF levels for nor-
mal control patients similar to our results for patients
with acyanotic congenital heart disease.22 We believe
the validity of the conclusions reached in this study is
supported by the concurrent performance of the
enzyme-linked immunosorbent assay on serum
obtained from children with acyanotic congenital heart
disease, with identical handling of the samples from
each group. 
Another weakness occurs in that, despite attempts to
balance the study groups for age, children with acya-
notic congenital heart disease were significantly older
than children with cyanotic congenital heart disease.
This was largely attributable to the fact that most of the
samples obtained in children with cyanotic congenital
heart disease were obtained during cardiac catheteriza-
tions before palliative operations performed in infancy.
The acyanotic group demonstrated conditions that
often did not require intervention in infancy such as
arrhythmias or progressive aortic valvular disease.
Several authors have looked at the influence of age on
bFGF and VEGF levels in patients with cancer, chil-
dren with inflammatory bowel disease, and children
with diabetes and have found no correlation.19,23,24
Rivard and colleagues25 reported an age–dependent
impaired angiogenic response to ischemia that was
probably due to a decrease in VEGF transcription.
However, this study compared tissue VEGF levels in
young versus elderly animals. There have been no stud-
ies to our knowledge that demonstrate a correlation of
serum VEGF levels with age. Lassus and colleagues26
measured plasma VEGF levels in neonates and found
levels similar to those reported in normal adults using
the same methods used in the present study.
Summary
The present study represents a preliminary attempt to
identify factors that may have an impact on manifesta-
tions of cyanotic congenital heart disease. VEGF
appears to be systemically elevated in patients with
chronic cyanosis and may contribute to the formation
of extensive collateral vessels that sometimes develop
in these children. Issues related to the exact origin of
these factors are not specifically answered by this
study. However, these findings may have broader
implications regarding the pathophysiologic features of
cyanotic heart disease, while further study of affected
children may aid in understanding the control mecha-
nisms of angiogenesis.
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